Equities Analysts Issue Forecasts for APLT FY2025 Earnings

Applied Therapeutics, Inc. (NASDAQ:APLT) – Equities researchers at William Blair upped their FY2025 EPS estimates for Applied Therapeutics in a research note issued to investors on Wednesday, May 14th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.64) per share for the year, up from their prior estimate of ($0.66). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.65) per share. William Blair also issued estimates for Applied Therapeutics’ FY2026 earnings at ($0.71) EPS.

Separately, Royal Bank of Canada reissued a “sector perform” rating and set a $1.50 price objective on shares of Applied Therapeutics in a report on Wednesday, May 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.10.

Applied Therapeutics Price Performance

NASDAQ APLT opened at $0.44 on Monday. Applied Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The stock’s 50-day moving average is $0.43 and its two-hundred day moving average is $1.79. The firm has a market cap of $61.66 million, a P/E ratio of -0.27 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT) last issued its quarterly earnings data on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.61 million.

Institutional Investors Weigh In On Applied Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of APLT. Vestal Point Capital LP lifted its position in Applied Therapeutics by 904.4% during the fourth quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company’s stock worth $9,846,000 after acquiring an additional 10,355,000 shares during the last quarter. Propel Bio Management LLC increased its stake in shares of Applied Therapeutics by 17.4% during the first quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company’s stock worth $5,517,000 after purchasing an additional 1,670,000 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Applied Therapeutics by 91.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company’s stock worth $5,076,000 after purchasing an additional 4,959,670 shares during the last quarter. VR Adviser LLC boosted its stake in Applied Therapeutics by 1.7% in the 4th quarter. VR Adviser LLC now owns 9,990,591 shares of the company’s stock valued at $8,554,000 after purchasing an additional 165,591 shares during the period. Finally, Schonfeld Strategic Advisors LLC grew its holdings in Applied Therapeutics by 2,458.3% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company’s stock valued at $7,502,000 after buying an additional 8,419,781 shares in the last quarter. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.